Autolus’ AUCATZYL sales jump 95% and its full-year outlook rises (NASDAQ: AUTL)

Posted by Joseph Casey on Nov 10th, 2026

What happened

Autolus Therapeutics plc (NASDAQ: AUTL) reported third-quarter AUCATZYL revenue of $41.2 million, up 95% from a year earlier, and raised its full-year outlook.

A year earlier the therapy brought in $21.1 million. Nine-month revenue reached $113.1 million, up 122% from the same period of 2025, according to the company's slides. Autolus now expects full-year 2026 AUCATZYL net product revenue at or above the top of its prior guidance range.

Key numbers

Metric	Latest	Change	Source
Q3 AUCATZYL net product revenue	$41.2 million	from $21.1 million, +95%	SEC 8-K, Exhibit 99.1
Nine-month AUCATZYL net product revenue	$113.1 million	from $51.05 million, +122%	SEC 8-K, Exhibit 99.2
Q3 gross margin	57%		SEC 8-K, Exhibit 99.1
Q3 loss from operations	$43.5 million	from $71.6 million, -39.2%	Calculated from SEC 8-K, Exhibit 99.1
Cash, equivalents and marketable securities at Sept. 30	$248.4 million		SEC 8-K, Exhibit 99.1

Where the growth comes from

The press release credits rising demand at treatment centers that already offer AUCATZYL, plus new centers. UK sales also added to the total. The FDA approved the therapy on Nov. 8, 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Dr. Christian Itin, the chief executive, said growth came mainly from existing authorized treatment centers as physicians gain positive experience. He pointed to real-world data from the ROCCA consortium. He called AUCATZYL's performance in adult leukemia a key near-term value driver.

The company's slides show 90 U.S. authorized treatment centers and mark a 2026 goal of more than 80 centers as achieved. More ROCCA real-world data is expected in December.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

Margins and costs

Gross margin reached 57% in the third quarter, up from 55% in the second quarter and negative in the third quarter of 2025. Cost of sales fell to $17.9 million from $28.6 million while revenue rose. Year-to-date gross margin is 44%, and the slides show a peak target of 65% to 70%.

Volume is not the whole story. The company says part of the gain over the prior year came from lower manufacturing cost per batch, thanks to higher volumes and efficiency work. It also cites lower inventory reserves and write-offs than a year earlier.

Research and development spending rose to $30.9 million from $27.9 million. The company ties this to higher clinical manufacturing supply costs. Selling, general and administrative expenses slipped to $35.9 million from $36.3 million. Loss from operations narrowed to $43.5 million from $71.6 million.

Net loss was $55.1 million, or $0.21 per share, against $79.1 million, or $0.30, in the third quarter of 2025. Other expenses, net, were $12.0 million, up from $7.0 million.

Cash and the balance sheet

Cash, cash equivalents and marketable securities were $248.4 million at Sept. 30, up from $201.6 million at June 30. The company says the increase came mainly from net cash inflows from its senior secured note facility with Perceptive Advisors.

Autolus expects its cash to fund operations into Q2 2028. That includes the first and second tranches of the facility, totaling $100 million, and anticipated AUCATZYL revenue. So the runway rests partly on facility proceeds and on revenue still to be earned.

Total shareholders' equity fell to $27.4 million at Sept. 30 from $178.1 million at Dec. 31, 2025, a drop of 84.6% by OptimistFi's calculation. Total liabilities rose to $495.7 million from $410.9 million.

Why it matters

OptimistFi has argued that AUCATZYL must win real-world adoption and positive unit economics before the balance sheet forces dilution. This quarter supports the first two parts. Demand grew in existing centers and gross margin is positive.

OptimistFi calculates that reaching the $150 million outlook requires at least $36.9 million of fourth-quarter revenue. That is less than the third quarter delivered. The raised outlook does not depend on further sequential growth.

The outlook is still guidance, not realized revenue. The runway depends on current operating plans, anticipated revenue and the Perceptive proceeds. With the equity cushion much smaller than at year-end, the financing question remains open. On balance the quarter strengthens the case.

What's next

Autolus expects to report initial Phase 1 data for AUTO8 in light-chain amyloidosis from the ALARIC trial at ASH on Dec. 12. That readout would show whether the pipeline adds to the story beyond AUCATZYL.

Updated CARLYSLE lupus data were scheduled for the American College of Rheumatology meeting on Nov. 10, with up to 25 months of follow-up in adults. The company also plans to move the first BOBCAT data in progressive multiple sclerosis to the ECTRIMS Global meeting in October 2027. Key opinion leaders said longer follow-up is needed.

By then it expects 12 months or more of follow-up for the first 12 patients and data in up to 24 patients. Phase 2 CATULUS data in pediatric leukemia are expected by year-end 2027, and Phase 2 LUMINA data in lupus nephritis in 2028.